drugset / Trial / NCT04627402

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

NCT04627402

RandomizedParallel-groupSingle-blindTreatment

Summary

This study aimed to compare intravitreous conbercept alone with conbercept plus intravitreous triamcinolone acetonide in DME eyes which showed limited response to anti-VEGF treatment after one injection.

Timeline

Start
2020-11-12
Primary completion
2021-06-01
Completion
2021-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified Intravitreal
Background Conbercept Protein / enzyme biologic Intravitreal